GeneDx Holdings (WGS) is back in focus after weak Q1 2026 results, a large Fabric Genomics impairment, and sharply reduced 2026 revenue guidance triggered a roughly 49% single day share price drop and multiple investor lawsuits.

That selloff sits against a volatile backdrop, with the share price now at US$56.33 after a 38.2% 1 month share price return but a year to date share price decline of 57.4%. The 3 year total shareholder return is up more than 7x, suggesting long term holders have still seen very large gains even as recent momentum has faded and legal risks move to the forefront.

If this kind of sharp swing has you thinking about diversification, it could be worth scanning other healthcare focused AI stocks using our curated screener, starting with 39 healthcare AI stocks.

With the stock still well below its recent highs and trading at a discount to some analyst targets, yet facing lawsuits, an impairment and lower guidance, are you looking at a mispriced recovery story or a market that already sees limited future growth?

Most Popular Narrative: 62.2% Undervalued

GeneDx Holdings' most followed narrative pegs fair value at about $148.89 per share, well above the last close at $56.33, which sets up a wide gap between market pricing and narrative expectations.

Rapid expansion into new and underpenetrated markets, including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties, positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates. Scaling proprietary AI powered genomic interpretation platforms and integrating newly acquired Fabric Genomics technology enhances efficiency and accuracy, which should both lower per sample costs and support margin expansion as the business grows.

Curious what kind of revenue trajectory and margin shift are built into that fair value, or how long it is assumed to take? The narrative leans on compounding data advantages, wider reimbursement and a sharply different earnings profile than today. If you want to see which specific growth and profitability milestones have to line up to close that gap, the full story is worth a closer look.

Result: Fair Value of $148.89 (UNDERVALUED)

However, the story can break if reimbursement tightens or if genetics competitors win share faster than GeneDx converts new pediatric and prenatal demand.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Market Ratios Point in a Different Direction

While the narrative fair value sits far above the current US$56.33 share price, the market is sending mixed messages. GeneDx trades on a P/S ratio of 3.8x versus 0.8x for direct peers and 1.2x for the wider US Healthcare sector, even though the fair ratio is 4.4x. For you, that raises a key question: is this a premium story still priced ahead of its group, or a case where sentiment has not yet closed the gap to that fair ratio?

Next Steps

Given the mix of concern and optimism running through this story, it makes sense to look at the data yourself and move quickly to form your own stance. A good place to start is by weighing both sides of the investment case through the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If GeneDx has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed themes using our screeners.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations through the 46 high quality undervalued stocks.
• Strengthen your core holdings by filtering for companies with resilient finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot opportunities the crowd might be missing by running the screener containing 21 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.